Post-Marketing Observational Study (PMOS) to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)
Phase of Trial: Phase IV
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms DEVOTE
- Sponsors AbbVie
- 09 Jul 2019 Planned number of patients changed from 50 to 70.
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2018 Status changed from not yet recruiting to recruiting.